Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis.

Autor:	Batskikh SN; A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health, Moscow, Russia., Vinnitskaya EV; A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health, Moscow, Russia., Sandler YG; A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health, Moscow, Russia., Кhaimenova TY; A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health, Moscow, Russia.
Jazyk:	angličtina
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2018 Nov 22; Vol. 90 (11), pp. 67-73.
DOI:	10.26442/terarkh2018901167-73
Abstrakt:	Today, there is no complete clarity about the pathogenetic mechanisms of the hepatic decompensation in patients with HCV-cirrhosis during the course of direct-acting antiviral (DAAs) therapy. The current article describes several clinical observations of decompensation (with the development of liver failure and portal hypertension) in cirrhotic patients during the course of DAAs-therapy of hepatitis C. The authors present contemporary views and their own assumptions about the possible mechanisms of the hepatic decompensation associated with DAAs-therapy in patients with liver cirrhosis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu